Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03789721
Other study ID # 2019NTLS027
Secondary ID MT2019-01
Status Recruiting
Phase
First received
Last updated
Start date May 1, 2019
Est. completion date February 2030

Study information

Verified date May 2024
Source Masonic Cancer Center, University of Minnesota
Contact Ashish Gupta, MD
Phone 612-626-2961
Email gupta461@umn.edu
Is FDA regulated No
Health authority
Study type Observational [Patient Registry]

Clinical Trial Summary

The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.


Description:

This is a prospective, non-therapeutic protocol designed to create and maintain a registry of participants with Adrenoleukodystrophy (ALD) and known/presumed mutation for ALD. This study also involves maintaining a prospective biorepository to collect and store buccal swab, blood, stool and urine samples as well. In this protocol, pediatric (including infants), adolescents and adult patients with confirmed or presumed ALD (based on positive VLCFA testing and/or confirmed mutation) will be offered potential study participation. Additionally, presumed mutation for ALD (based on pedigree or confirmed mutation) will be offered potential study participation. After appropriate consent (online or in-person), subjects will be requested to provide a medical history (with authorization of release of medical records), longitudinal biospecimens, and permission to perform laboratory analyses on these samples. The overall goal is to understand the natural disease course in affected and unaffected patients (identified patients and relatives with a diagnosis of ALD), as well as women with ALD to assemble a resource of clinical, medical, and biological data from the participants. This study also aims to understand the outcomes of this disease, as well as possibly develop biomarkers to identify prognostic markers for disease progression, which may help develop effective interventions. The biospecimen bank and registry will provide access to samples and data for the ongoing studies as well as will provide an important resource for the future research.


Recruitment information / eligibility

Status Recruiting
Enrollment 1000
Est. completion date February 2030
Est. primary completion date February 2030
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria - Age 0 - 100 - ALD patients or family member meeting any of the following criteria: - Any patient diagnosed with ALD (confirmed by positive VLCFA testing and/or genetic mutation). - Known or presumed mutation with ALD based on pedigree or confirmed mutation in ABCD1 gene - Participants living in the United States and territories Exclusion Criteria - Patients diagnosed with ALD who lack the capacity to consent/assent AND do not have a designated legally authorized representative or guardian. - Patients who have undergone BMT or other cellular therapy . - Patients not fluent in English who are unable to consent in-person at the BMT Journey Clinic. - Patients who are illiterate - Patient determined by the PI or designee to be unlikely to complete required study components (due to language barriers, compliance issues, etc.)

Study Design


Intervention

Other:
Medical Record Abstraction
Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually.
Biospecimen Sample Collection
Collect research samples, when feasible for those diagnosed with ALD.

Locations

Country Name City State
United States Masonic Cancer Center at University of Minnesota Minneapolis Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Masonic Cancer Center, University of Minnesota

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Collect Clinical and Epidemiological Data Collect clinical and epidemiological data through medical record abstraction and self-reported questionnaire survey semi-annually. 10 Years
See also
  Status Clinical Trial Phase
Recruiting NCT02254863 - UCB Transplant of Inherited Metabolic Diseases With Administration of Intrathecal UCB Derived Oligodendrocyte-Like Cells Phase 1
Completed NCT00383448 - HSCT for High Risk Inherited Inborn Errors Phase 2
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT02961803 - MD1003-AMN MD1003 in Adrenomyeloneuropathy Phase 2/Phase 3
Withdrawn NCT02948062 - Early Diagnosis Of Childhood Cerebral ALD
Completed NCT02952482 - Newborn Screening for Adrenoleukodystrophy
Completed NCT04303416 - Plasma Exchange With Albumin in AMN Patients Phase 2/Phase 3
Terminated NCT00545597 - A Phase III Trial of Lorenzo's Oil in Adrenomyeloneuropathy Phase 3
Completed NCT03513328 - Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation Phase 1/Phase 2
Active, not recruiting NCT02699190 - LeukoSEQ: Whole Genome Sequencing as a First-Line Diagnostic Tool for Leukodystrophies
Recruiting NCT02559830 - Autologous Hematopoietic Stem Cell Gene Therapy for Metachromatic Leukodystrophy and Adrenoleukodystrophy Phase 1/Phase 2
Recruiting NCT00278044 - Clinical Study and Gene Mutation Analysis of Adrenoleukodystrophy in Taiwanese Children N/A
Completed NCT00176904 - Stem Cell Transplant for Inborn Errors of Metabolism Phase 2/Phase 3
Completed NCT00007020 - Compassionate Treatment of Patients With Inborn Errors of Bile Acid Metabolism With Cholic Acid Phase 3
Active, not recruiting NCT03231878 - A Clinical Study to Evaluate the Efficacy and Safety of MIN-102 (IMP) in Male AMN Patients. Phase 2/Phase 3
Recruiting NCT03047369 - The Myelin Disorders Biorepository Project
Recruiting NCT04925349 - Modeling Macrophages Activation Pattern in X-linked Adrenoleukodystrophy, Metachromatic Leukodystrophy and Adult Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia
Active, not recruiting NCT00005900 - Study of Pulmonary Complications in Pediatric Patients With Storage Disorders Undergoing Allogeneic Hematopoietic Stem Cell Transplantation N/A
Completed NCT00004450 - Randomized Study of Beta Interferon and Thalidomide in Patients With Adrenoleukodystrophy N/A
Recruiting NCT04090268 - Precision Exercise in Children With Malignant Hemopathies N/A